Platelet

Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)

Retrieved on: 
Wednesday, March 6, 2024

“Previous progression-free survival and interim OS data from the NORA study demonstrated the benefit of niraparib maintenance therapy with an individualized starting dose among Chinese patients with PSROC,” said Dr. Rafael Amado, President, Head of Global Oncology Research and Development, Zai Lab.

Key Points: 
  • “Previous progression-free survival and interim OS data from the NORA study demonstrated the benefit of niraparib maintenance therapy with an individualized starting dose among Chinese patients with PSROC,” said Dr. Rafael Amado, President, Head of Global Oncology Research and Development, Zai Lab.
  • “We look forward to sharing the final OS findings from this study at both the 2024 ESGO and SGO conferences.
  • The final OS analysis was conducted after ≥ 50% of OS events occurred in the intent-to-treat population.
  • No new safety signals were identified during the long-term follow up period subsequent to the primary analysis.

BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA

Retrieved on: 
Tuesday, February 27, 2024

“In clinical trials, TEVIMBRA has demonstrated its potential to improve survival for patients with gastric and gastroesophageal junction cancer.

Key Points: 
  • “In clinical trials, TEVIMBRA has demonstrated its potential to improve survival for patients with gastric and gastroesophageal junction cancer.
  • Median progression-free survival for TEVIMBRA plus chemotherapy was 6.9 months vs. 6.2 months respectively; (HR: 0.78 [95% CI: 0.67, 0.90]).
  • The safety profile for TEVIMBRA in combination with chemotherapy was manageable and in line with the known safety profile of anti-PD-1 antibodies.
  • A BLA for the treatment of patients with advanced or metastatic ESCC after prior chemotherapy is also under review by the FDA.

Family Dentistry of Frisco Introduces Advanced Dental Implant Solutions with Innovative PRP Technique and Comprehensive Sedation Options

Retrieved on: 
Wednesday, March 6, 2024

FRISCO, Texas, March 5, 2024 /PRNewswire-PRWeb/ -- Family Dentistry of Frisco, under the esteemed leadership of Dr. Paresh B. Patel, DDS, is proud to announce the expansion of its dental services to include state-of-the-art Dental Implants and Implant Supported Dentures, commonly referred to as All-on-4. These advanced treatments are now enhanced by the innovative use of Platelet-Rich Plasma (PRP) technology, setting a new standard in dental care excellence and patient comfort in the Frisco area.

Key Points: 
  • Family Dentistry of Frisco has proudly announced the introduction of its advanced dental implant solutions, featuring the innovative Platelet-Rich Plasma (PRP) technique and a wide range of comprehensive sedation options.
  • At the forefront of dental technology, Family Dentistry of Frisco incorporates PRP in implant procedures to accelerate healing and improve the success rate of dental implants.
  • Understanding the importance of comfort and ease for our patients, Family Dentistry of Frisco offers multiple levels of sedation dentistry to ensure a calm and pain-free experience during dental implant procedures.
  • The introduction of PRP technology and our comprehensive sedation options exemplify our commitment to pioneering dental treatments that prioritize patient well-being and satisfaction."

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Retrieved on: 
Friday, January 5, 2024

Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Clopidogrel Krka, clopidogrel, Date of authorisation: 23/09/2009, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Clopidogrel Krka, clopidogrel, Date of authorisation: 23/09/2009, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Clopidogrel Krka, clopidogrel, Date of authorisation: 23/09/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Date of authorisation: 18/05/2020, Revision: 14, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Date of authorisation: 18/05/2020, Revision: 14, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Date of authorisation: 18/05/2020, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Date of authorisation: 09/03/2004, Revision: 24, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Date of authorisation: 09/03/2004, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Date of authorisation: 09/03/2004, Revision: 24, Status: Authorised